NCT01511510View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Schizophrenia
Interventions
DRUG

PF-04958242

PF-04958242 0.05 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.10 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.15 mg oral solution Q24 hours for 14 days

DRUG

PF-04958242

PF-04958242 0.25 mg oral solution Q24 hours for 14 days

DRUG

Placebo

Placebo oral solution Q24 hours for 14 days

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY